.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Fuji
Healthtrust
Deloitte
Boehringer Ingelheim
Queensland Health
Accenture
QuintilesIMS
Fish and Richardson
Farmers Insurance

Generated: December 16, 2017

DrugPatentWatch Database Preview

Patents Expiring in March 2032

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
The Medicines CoIONSYSfentanyl hydrochlorideSYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006RXYesYes► Subscribe► SubscribeYMETHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
Novartis Pharms CorpILEVROnepafenacSUSPENSION/DROPS;OPHTHALMIC203491-001Oct 16, 2012RXYesYes► Subscribe► SubscribeY
Bayer HealthcareALIQOPAcopanlisib dihydrochloridePOWDER;IV (INFUSION)209936-001Sep 14, 2017RXYesYes► Subscribe► Subscribe
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-002Jul 27, 2016RXYesYes► Subscribe► SubscribeY
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes► Subscribe► SubscribeY
Mallinckrodt IpOFIRMEVacetaminophenSOLUTION;IV (INFUSION)022450-001Nov 2, 2010APRXYesYes► Subscribe► SubscribeY
Pohl BoskampGONITROnitroglycerinPOWDER;SUBLINGUAL208424-001Jun 8, 2016RXYesYes► Subscribe► SubscribeY
Horizon Theraps IncRAVICTIglycerol phenylbutyrateLIQUID;ORAL203284-001Feb 1, 2013RXYesYes► Subscribe► SubscribeDOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER
Horizon Theraps IncRAVICTIglycerol phenylbutyrateLIQUID;ORAL203284-001Feb 1, 2013RXYesYes► Subscribe► SubscribeDOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER
Horizon Theraps IncRAVICTIglycerol phenylbutyrateLIQUID;ORAL203284-001Feb 1, 2013RXYesYes► Subscribe► SubscribeTREATMENT OF A UREA CYCLE DISORDER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Dow
Cerilliant
Moodys
Farmers Insurance
McKinsey
Federal Trade Commission
Johnson and Johnson
Accenture
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot